ZBTB7A Antibody
| Code | Size | Price |
|---|
| PSI-6127-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-6127-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
ZBTB7A Antibody: LRF, FBI1, FBI-1, ZBTB7, ZNF857A, pokemon, LRF, Zinc finger and BTB domain-containing protein 7A, Factor binding IST protein 1
Application Note:
ZBTB7A antibody can be used for detection of ZBTB7A by Western blot at 1 - 2 μg/mL. Antibody can also be used for immunohistochemistry starting at 2.5 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Background:
ZBTB7A Antibody: The ZBTB family of proteins is comprised of diverse zinc finger proteins that also contain a BTB (BR-C, ttk and bab) domain. ZBTB7A, also known as LRF, was initially identified as a potential target of the LAZ-3/BCL-6 oncogene. Later reports demonstrated that it could bind to the wild-type IST (inducer of short transcripts) elements of HIV-1 long terminal repeats (LTRs) and stimulate Tat activity on the HIV-1 LTR. More recently it ZBTB7A has been recognized as a proto-oncogene whose overexpression contributes to malignancy in breast cancer and functions as a co-repressor of the androgen receptor in prostate cancer cells.
Background References:
- Filion GJP, Zhenilo S, Salozhin S, et al. A family of zinc finger proteins that bind methylated DNA and repress transcription. Mol. Cell. Biol.2006; 26:169-81.
- Davies JM, Hawe N, Kabarowski J, et al. Novel BTB/POZ domain zinc-finger protein, LRF, is a potential target of the LAZ-3/BCL-6 oncogene. Oncogene1999; 18:365-75.
- Pendergrast PS, Wang C, Hernandez N, et al. FBI-1 can stimulate HIV-1 Tat activity and is targeted to a novel subnuclear domain that includes the Tat-P-TEFb-containing nuclear speckles. Mol. Cell. Biol.2002; 13:915-29.
- Qu H, Qu D, Chen F, et al. ZBTB7 overexpression contributes to malignancy in breast cancer. Cancer Invest.2010; 28:672-8.
Buffer:
ZBTB7A Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted species reactivity based on immunogen sequence: Rat: (94%), Chicken: (88%)
Immunogen:
ZBTB7A antibody was raised against a 16 amino acid synthetic peptide near the amino terminus of human ZBTB7A.
The immunogen is located within the first 50 amino acids of ZBTB7A.
The immunogen is located within the first 50 amino acids of ZBTB7A.
NCBI Gene ID #:
51341
NCBI Official Name:
zinc finger and BTB domain containing 7A
NCBI Official Symbol:
ZBTB7A
NCBI Organism:
Homo sapiens
Physical State:
Liquid
Protein Accession #:
AAH84568
Protein GI Number:
7705375
Purification:
ZBTB7A Antibody is affinity chromatography purified via peptide column.
Research Area:
Cancer,Cell Cycle
SPECIFICITY:
At least two isoforms of ZBTB7A are known to exist; this antibody will recognize both isoforms. This antibody is predicted to not cross-react with other ZBTB protein family members.
Swissprot #:
O95365
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | ZBTB7A Peptide | PSI-6127P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|